Navigation Links
Ondine Biopharma Announces Second Quarter 2008 Financial Results
Date:8/14/2008

VANCOUVER, Aug. 14 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (the "Company" or "Ondine", TSX: OBP; AIM: OBP) a medical technology company developing photodisinfection based products, today announced its financial results for the second quarter ended June 30, 2008.

"During the past quarter we made significant regulatory and clinical progress with our photodisinfection technology and we are leveraging our successes to advance discussions with prospective strategic partners," stated Carolyn Cross, Ondine's President & CEO, "We also took steps to build on our technology as we see the opportunity to address many unmet medical needs with our photodisinfection platform. Accordingly, having validated Periowave (TM) in the Canadian dental market, we are refocusing our resources on new product development and obtaining appropriate strategic partners for the commercialization and co-development of our photodisinfection-based product pipeline."

2008 Second Quarter Results and Recent Developments

FINANCIAL RESULTS

For the quarter ended June 30, 2008 (the "Second Quarter of 2008"), the Company recorded a loss of $2.43 million or $0.04 per common share compared with a loss of $3.79 million or $0.07 per common share during the quarter ended June 30, 2007 (the "Second Quarter of 2007"). For the six months ended June 30, 2008 (the "First Half of 2008"), the Company recorded a loss of $4.9 million or $0.08 per common share compared with a loss of $7.24 million or $0.13 per common share during the six months ended June 30, 2007 (the "First Half of 2007"). Product sales of our laser base stations and treatment kits during the Second Quarter of 2008 amounted to $0.26 million with a gross margin of $0.18 million (69.8%) compared to product sales of $0.51 million and a gross margin of $0.23 million (45.6%) during the Second Quarter of 2007. Product sales of our laser base stations and treatment kits during the First Half of 2008 amounted
'/>"/>

SOURCE Ondine Biopharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Ondine to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
8. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
9. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
10. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... BlueInGreen announces the ... sales network. The business venture will bring the ... Atlantic Provinces, exclusively through Resource Systems. , Since ... Canada’s premiere manufacturing representative firms, hosting a diverse ... and wastewater markets. More information on Resource Systems ...
(Date:3/3/2015)... March 3, 2015 Fried, Frank, Harris, Shriver ... Lewis has joined the Firm as a partner ... New York office. Mr. Lewis ... as well as other intellectual property and general litigation. ... Lewis represents both plaintiffs and defendants in a range ...
(Date:3/3/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or ... Expert Opinion on Biological Therapy , Dr. Michael ... , at the Henry Ford Hospital in ... (TB4) has the capacity to promote CNS and peripheral ... leading to neurological recovery in each case.  They pointed ...
(Date:3/3/2015)... IRVINE, Calif. , March 3, 2015 AtheroNova ... subsidiary, AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 ... Central District of California , ... 2, 2015. The Company,s Chapter 11 cases are expected to ... options, including a Bankruptcy Court supervised asset sale process, for ...
Breaking Biology Technology:BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... (GFP) in their retina cells or other tissues can ... real time computer record of movement and gene expression. ... BMC Biotechnology , will allow detailed analyses of ... Tower led a team of researchers from the University ...
... Washington Life Sciences Discovery,Fund (LSDF) has awarded nearly $4.7 ... Alliance (WAVA) and to support initial research into,three new ... the,grant is funded by Washington,s$350 million tobacco-lawsuit-settlement bonus,and provides ... , WAVA core ...
... Office has,issued Nutraceutix, Inc. a patent for BIO-tract. It ... the technology has been awarded based,on BIO-tract,s ability to ... their way to optimal release sites in the,intestinal tract. ... Nutraceutix comments: "Many years ago,we recognized the need for ...
Cached Biology Technology:Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 2Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 4Probiotic Delivery Technology Awarded Third International Patent 2
(Date:2/5/2015)... , Jan. 28, 2015 Research and ... the addition of the "Global Biometrics Market ... Regions and Countries " report to their offering. ... Asia-Pacific is anticipated to ... 2015, owing to increasing government spending towards IT ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to ... biometrics technology is to ensure that an individual is who ... technology may make use of a person,s unique physical characteristics, ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... 2012 /PRNewswire-iReach/ -- Global Information Inc is pleased ... new research tool for cancer drug research and development companies ... Drug targets and their pathways are the ... of cancer. The Oncology Drug Pathway Analyzer from BioSeeker Group ...
... WASHINGTON, June 5, 2012  President Barack Obama has made ... security of the United States.  To ensure that the ... 6, in Washington, D.C., his administration will convene a ... to discuss the major cyber security issues affecting the ...
... Washington, DCJune 6, 2012 Anthony R. Richardson, Ph.D., Assistant ... Carolina Hill School of Medicine, has been honored with ... Awards. These awards, given annually to two young scientists ... medical microbiology and infectious diseases, are presented in memory ...
Cached Biology News:New Tool Helps Drug Developers Optimize Their Research and Target Development for Better Results and a Stronger Competitive Edge 2New Tool Helps Drug Developers Optimize Their Research and Target Development for Better Results and a Stronger Competitive Edge 3Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 2Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 3The American Society for Microbiology honors Anthony R. Richardson 2
... is a fluorescent counterstain which ... color. The bright blue fluorescence ... fluorochromes such as rhodamine, Cy3, ... can be used for fluorescent ...
Contact us for more information...
... Most sensitive silver stain. ... No stop baths or reversers ... lipids and polysaccharides. Linear ... to stain multiple gels per ...
... you to insert a transposable element of ... in vitro transposition. It uses TnsABC* Transposase ... DNA target. Target DNA may be a ... on your interests (6-8). If the insertion ...
Biology Products: